...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Phase 1b/2 trial expected to initiate 1Q 2019

aaacccchhhh,,,,,Bear,,,surely we must have learned by now from past history that our team generally can't meet their guidelines or milestones for time or money!!!,,,,,we definitely shouldn't expect to be disappointed when time lines are given,,they are actually meaningless to Management. Which is a real issue to those on the sidelines watching our sister company.... jmo

Share
New Message
Please login to post a reply